Homology is a genetic medicines company translating proprietary, next generation gene editing and gene therapy technology into novel treatments for patients with rare diseases.
The combination of a management team that has successfully developed and commercialized rare disease therapies, and a new multidimensional technology platform uniquely positions the Company to move beyond the current limitations of gene therapy and editing approaches to improve patient care.
Homology Medicines has built foundational intellectual property on gene editing and gene therapy vectors derived from naturally occurring human adeno-associated viruses (AAVs). The Company's technology is precise, on-target and highly efficient for in vivo editing of genetic mutations. The unique team and technology create a significant opportunity for Homology to rapidly advance a diverse pipeline of new medicines that address and potentially cure the underlying cause of genetic diseases.
January 3, 2017
Homology Named Top 20 Life Science Startups to Watch in 2017
Homology Featured in PharmaVoice's Trending 2017: Gene Editing